文献速递抗栓抗凝管理特殊人群用药

美国癌症合并房颤患者口服抗凝药使用趋势(2010-2016)

Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010-2016.
PubMed 文献 · Pharmacotherapy · 2022-04-14

基于SEER-Medicare数据,纳入27702例≥66岁新诊断非瓣膜性房颤的癌症患者,分析2010-2016年口服抗凝药使用情况。结果显示仅16.1%用DOAC、12.9%用华法林,2016年近7成未启动抗凝;DOAC使用比例从2011年21.8%升至2016年76.2%,但高卒中风险者DOAC使用少于华法林。

要点

  • 癌症合并NVAF患者抗凝治疗率低,2016年近70%未启动抗凝。
  • DOAC使用比例从2011年21.8%升至2016年76.2%,华法林相应下降。
  • 高CHA₂DS₂-VASc评分者抗凝可能性更高,但DOAC使用少于华法林。

核心结论

  • 癌症合并NVAF患者中近7成未接受抗凝治疗,DOAC使用逐年增加但高卒中风险者DOAC使用少于华法林。

研究设计与样本

  • 基于SEER-Medicare数据库的回顾性队列研究,纳入2010-2016年新诊断NVAF的≥66岁癌症患者27702例。

主要发现

  • 27702例中4469例(16.1%)使用DOAC,3577例(12.9%)使用华法林。
  • 8046例抗凝使用者中,DOAC比例从2011年21.8%升至2016年76.2%,华法林从78.2%降至23.8%。
  • 2016年近7成癌症合并NVAF患者未启动抗凝。
  • 抗凝使用与较高CHA₂DS₂-VASc评分相关(评分≥6 vs 1:HR 1.55,95%CI 1.27-1.90),与较低HAS-BLED评分相关(评分1 vs ≥6:HR 1.96,95%CI 1.67-2.30)。
  • 抗凝使用者中,较高CHA₂DS₂-VASc评分者DOAC使用少于华法林(评分≥6 vs 1:OR 0.53,95%CI 0.33-0.84)。

临床怎么用

  • 临床应关注癌症合并NVAF患者的抗凝启动率,尤其高卒中风险者。
  • 高CHA₂DS₂-VASc评分患者中DOAC使用少于华法林,需个体化评估抗凝方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anticoagulation among patients with cancer and atrial fibrillation is challenging due to elevated risk of bleeding and stroke. We characterized use of oral anticoagulants among patients with cancer and non-valvular atrial fibrillation (NVAF). METHODS: We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data and included patients with cancer aged ≥66 years with an incident diagnosis of NVAF from 2010 to 2016. We used a Cox proportional hazard model and multivariable logistic regression to identify factors associated with anticoagulant use versus no use and direct oral anticoagulants (DOACs) versus warfarin use, respectively. RESULTS: Of 27,702 patients with cancer and NVAF, 4469 (16.1%) used DOACs and 3577 (12.9%) used warfarin. Among 8046 anticoagulant users, DOACs use increased from 21.8% in 2011 to 76.2% in 2016, with a corresponding decline in warfarin use from 78.2% to 23.8%. Nearly 7 out of 10 patients with cancer and NVAF did not initiate anticoagulation in 2016. Anticoagulant use was more likely among those with higher CHA₂DS₂-VASc scores (hazard ratio [HR] 1.55, 95% confidence interval [CI] 1.27-1.90 for score ≥6 vs. 1) or with lower HAS-BLED scores (HR 1.96, 95% CI 1.67-2.30 for score 1 vs. ≥6). Among anticoagulant users, DOAC use was less likely than warfarin in those with higher CHA₂DS₂-VASc scores (odds ratio [OR] 0.53, 95% CI 0.33-0.84 for score ≥6 vs. 1). CONCLUSIONS: Nearly 7 out of 10 patients with cancer and NVAF did not receive anticoagulation. Use of DOACs increased from 2010 to 2016, with a corresponding decline in warfarin use. DOACs are used less than warfarin among those at higher risk of stroke.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Ardeshirrouhanifard S, An H, Goyal RK, et al. Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010-2016. Pharmacotherapy. 2022. PMID: 35364622. doi:10.1002/phar.2679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。